The registered COVID-19 vaccineNo. 1 comes from Russia. This vaccine was developed as early as August 2020. Now COVID-19 vaccine in all countries is almost finished, and basically it can be marketed as long as the testing is finished. Success is inseparable from the scientific research team and financial strength behind it. Of course, the warriors who participated in the vaccine test also contributed their valuable strength.

1. Study on COVID-19 Vaccine —— Taking China Biology of Sinopharm Group as an example. As early as the discovery of this virus, they went to Wuhan to investigate the relevant situation of this virus. After various tests, they confirmed that this virus is a new type of virus. Since then, they have begun to study this virus. For this research, they invested a lot of money and personnel and collected thousands of volts of plasma for testing. Unexpectedly, a vaccine was developed in COVID-19.

Finally, after many months' efforts, they developed a vaccine for neocoronary pneumonia, which was tested in 1 and the second stage. The results showed that 1 and the second stage had good effects, and all the people vaccinated had no adverse reactions. The third phase of testing is now underway and it is expected to be listed at the end of 2020.

Second, the contribution of COVID-19 vaccine The research on such a new type of vaccine, of course, can not be separated from the efforts of many researchers, in addition to researchers and related staff. It is also important to be brave enough to accept new vaccine trials. Whether a vaccine can be marketed depends on its actual effect, and the role of these experimenters who accept the new vaccine is very important. So far, almost thousands of people have taken part in the test. It is reported that the cost of vaccine research in COVID-19 is basically around 2 billion.

Three. Research situation: Russian vaccine research was completed in August, and senior Russian personnel had been vaccinated at that time. Later, the vaccine was tested in 1 and the second phase. Now it is the third phase of testing, and the vaccines in Europe and America will probably be available at the end of 1 1.